# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
FDA accepts Rocket Pharmaceuticals' resubmission for Kresladi gene therapy in severe LAD-I, with a decision expected by Mar...
Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $11 price ta...
Prescription Drug User Fee Act (PDUFA) target action date is March 28, 2026All primary and secondary endpoints were met, and KR...
Leerink Partners analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the p...
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questi...
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangemen...